PCRX Pacira BioSciences Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: PCRX

Price (delayed)

$26.49

Market cap

$1.23B

P/E Ratio

29.11

Dividend/share

N/A

EPS

$0.91

Enterprise value

$1.66B

Pacira BioSciences, Inc.is the industry leader in its commitment to non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. The company's long-acting local ...

Highlights
The company's net income has surged by 164% YoY
Pacira BioSciences's EPS has surged by 160% YoY
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Website: http://www.pacira.com
Peers: DRRX HRTX CPIX CARA

Key stats

What are the main financial stats of PCRX
Market
Shares outstanding
46.5M
Market cap
$1.23B
Enterprise value
$1.66B
Valuations
Price to earnings (P/E)
29.11
Price to book (P/B)
1.41
Price to sales (P/S)
1.81
EV/EBIT
20.3
EV/EBITDA
10.56
EV/Sales
2.47
Earnings
Revenue
$674.98M
EBIT
$82.01M
EBITDA
$157.58M
Free cash flow
$139.49M
Per share
EPS
$0.91
Free cash flow per share
$3.02
Book value per share
$18.74
Revenue per share
$14.6
TBVPS
$20.07
Balance sheet
Total assets
$1.57B
Total liabilities
$704.26M
Debt
$586.04M
Equity
$870.13M
Working capital
$412.61M
Liquidity
Debt to equity
0.67
Current ratio
5.24
Quick ratio
3.94
Net debt/EBITDA
2.75
Margins
EBITDA margin
23.3%
Gross margin
72.6%
Net margin
6.2%
Operating margin
13%
Efficiency
Return on assets
2.7%
Return on equity
5.1%
Return on invested capital
6.4%
Return on capital employed
5.6%
Return on sales
12.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

PCRX stock price

How has the Pacira BioSciences stock price performed over time
Intraday
1.49%
1 week
-1.41%
1 month
-7.6%
1 year
-44.23%
YTD
-21.49%
QTD
-9.34%

Financial performance

How have Pacira BioSciences's revenue and profit performed over time
Revenue
$674.98M
Gross profit
$490.31M
Operating income
$87.68M
Net income
$41.96M
Gross margin
72.6%
Net margin
6.2%
The company's net income has surged by 164% YoY
Pacira BioSciences's net margin has soared by 158% YoY
The company's operating income has surged by 97% QoQ and by 46% YoY
PCRX's operating margin has soared by 94% QoQ and by 44% YoY

Growth

What is Pacira BioSciences's growth rate over time

Valuation

What is Pacira BioSciences stock price valuation
PCRX P/E details
P/E
29.11
P/B
1.41
P/S
1.81
EV/EBIT
20.3
EV/EBITDA
10.56
EV/Sales
2.47
Pacira BioSciences's EPS has surged by 160% YoY
PCRX's P/B is 62% below its 5-year quarterly average of 3.7 and 34% below its last 4 quarters average of 2.1
The equity has increased by 12% year-on-year and by 4.6% since the previous quarter
The price to sales (P/S) is 59% lower than the 5-year quarterly average of 4.4 and 28% lower than the last 4 quarters average of 2.5

Efficiency

How efficient is Pacira BioSciences business performance
Pacira BioSciences's ROA has soared by 200% YoY
PCRX's ROE has soared by 143% year-on-year
Pacira BioSciences's ROIC has soared by 129% from the previous quarter and by 88% YoY
Pacira BioSciences's return on sales has surged by 112% QoQ and by 51% YoY

Dividends

What is PCRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for PCRX.

Financial health

How did Pacira BioSciences financials performed over time
The total assets is 124% greater than the total liabilities
The current ratio has soared by 55% YoY and by 10% from the previous quarter
The company's quick ratio has surged by 50% YoY and by 11% QoQ
Pacira BioSciences's debt is 33% less than its equity
Pacira BioSciences's debt to equity has decreased by 32% YoY and by 6% from the previous quarter
Pacira BioSciences's debt has decreased by 23% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.